Cahill Represents Financing Sources in Valeant and Biovail Merger
Date: 06/21/10
Cahill is representing the financing sources in connection with providing $2.8 billion of financing for the merger of specialty pharmaceuticals companies Valeant Pharmaceuticals International and Canada's Biovail Corp.
Related Attorneys:
Noah B. Newitz,
Related Practices:
Antitrust & Trade Regulation,
Corporate,
Employee Benefits & Executive Compensation,
Environmental,
Intellectual Property,
Litigation,
Tax
|
